0000878088-12-000042.txt : 20120521 0000878088-12-000042.hdr.sgml : 20120521 20120521125716 ACCESSION NUMBER: 0000878088-12-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120517 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20120521 DATE AS OF CHANGE: 20120521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAR PHARMACEUTICAL COMPANIES, INC. CENTRAL INDEX KEY: 0000878088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223122182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10827 FILM NUMBER: 12857667 BUSINESS ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-802-4000 MAIL ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: PHARMACEUTICAL RESOURCES INC DATE OF NAME CHANGE: 19940526 8-K 1 form8ksubmissionof2012matter.htm FORM 8-K Converted by EDGARwiz



SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

______________________


FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported):  May 17, 2012


PAR PHARMACEUTICAL COMPANIES, INC.

(Exact name of registrant as specified in its charter)



Delaware

File Number 1-10827

22-3122182

(State or other jurisdiction of

(Commission File Number)

(I.R.S. Employer

incorporation or organization)


Identification No.)





300 Tice Boulevard, Woodcliff Lake, NJ

07677

(Address of principal executive offices)

(Zip Code)


Registrant’s telephone number, including area code: (201) 802-4000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







1

Item 5.07    Submission of Matters to a Vote of Security Holders


We held our annual stockholders’ meeting on May 17, 2012, at which a quorum was present.  At the annual meeting, our stockholders (i) elected Peter S. Knight and Thomas P. Rice to serve as our Class I directors for a three-year term expiring at the 2015 annual meeting of stockholders, (ii) ratified Deloitte & Touche LLP as our independent registered public accounting firm for the 2012 fiscal year, (iii) approved our 2012 omnibus incentive plan as set forth in our Proxy Statement filed with the Securities and Exchange Commission on March 30, 2012, and (iv) approved the non-binding advisory vote on our 2011 executive compensation programs and policies for our Named Executives (as described in the Compensation Discussion and Analysis set forth in our Proxy Statement).


The following are the voting results for these proposals:


PROPOSAL 1 – Election of Class I directors for a three-year term expiring at the 2015 annual meeting of stockholders:

For

Withheld

Broker Non-Votes




Peter S. Knight

29,969,702

1,310,633

2,433,458

Thomas P. Rice

30,236,627

1,043,708

2,433,458


PROPOSAL 2 – Ratification of Deloitte & Touche LLP as our independent registered public accounting firm for 2012:


For

Against

Abstain

Broker Non-Votes




33,296,412

406,243

11,138

0


PROPOSAL 3 – Approval of our 2012 Omnibus Incentive Plan:


For

Against

Abstain

Broker Non-Votes




22,046,742

9,207,571

26,022

2,433,458


PROPOSAL 4 – Non-binding advisory vote on our 2011 executive compensation programs and policies for our Named Executives:


For

Against

Abstain

Broker Non-Votes




26,560,126

4,442,996

277,213

2,433,458







2

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Dated as of:  May 21, 2012



PAR PHARMACEUTICAL COMPANIES, INC.

(Registrant)



/s/ Thomas J. Haughey

Thomas J. Haughey, President






3